Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 10:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–682 of 682 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: i-scan Clear all
Recruiting Phase 2 Interventional

Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma

NCT07150715
View directory record Official record
Conditions
Oligometastatic Prostate Adenocarcinoma, Recurrent Prostate Adenocarcinoma
Interventions
Actinium Ac 225 Vipivotide Tetraxetan, Biospecimen Collection, Gallium Ga 68 Gozetotide, Lutetium Lu 177 Vipivotide Tetraxetan, PSMA PET-CT Scan, Stereotactic Body Radiation Therapy
Drug · Procedure · Other + 1 more
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 31, 2026, 10:29 PM EDT
Not yet recruiting Phase 3 Interventional

PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glioblastoma

NCT06448286
View directory record Official record
Conditions
Glioblastoma
Interventions
Chemical Exchange Saturation Transfer Magnetic Resonance Imaging, Contrast-enhanced Magnetic Resonance Imaging, Magnetic Resonance Imaging, Radiation Therapy, Surgical Procedure, Temozolomide
Procedure · Radiation · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 31, 2026, 10:29 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study To Evaluate Hypofractionated Proton Therapy Or IMRT For Recurrent, Oligometastatic Prostate Cancer

NCT04190446
View directory record Official record
Conditions
Metastatic Prostate Adenocarcinoma, Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Intensity-Modulated Radiation Therapy, Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration, Computed Tomography, Magnetic Resonance Imaging, Biospecimen Collection
Radiation · Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 31, 2026, 10:29 PM EDT
Recruiting Phase 3 Interventional

Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

NCT07215910
View directory record Official record
Conditions
Astrocytoma, IDH-Mutant, Grade 3
Interventions
Intensity-Modulated Radiation Therapy, Volume Modulated Arc Therapy, Pencil Beam Scanning, Intensity-Modulated Proton Therapy, Temozolomide, Vorasidenib, Placebo Administration, Biospecimen Collection, Magnetic Resonance Imaging, Questionnaire Administration
Radiation · Procedure · Drug + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
12 Years and older
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2040
U.S. locations
152
States / cities
Bakersfield, California • Duarte, California • Dublin, California + 119 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 31, 2026, 10:29 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

NCT04068194
View directory record Official record
Conditions
Locally Advanced Malignant Solid Neoplasm, Locally Advanced Unresectable Cholangiocarcinoma, Locally Advanced Unresectable Gallbladder Carcinoma, Locally Advanced Unresectable Malignant Solid Neoplasm, Metastatic Cholangiocarcinoma, Metastatic Gallbladder Carcinoma, Metastatic Malignant Solid Neoplasm, Stage III Gallbladder Cancer AJCC v8, Stage IV Gallbladder Cancer AJCC v8, Unresectable Malignant Solid Neoplasm
Interventions
Avelumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Hypofractionated Radiation Therapy, Peposertib
Drug · Procedure · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
46
States / cities
Duarte, California • Irvine, California • La Jolla, California + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 31, 2026, 10:29 PM EDT
Recruiting Phase 3 Interventional

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

NCT07388524
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma
Interventions
Atezolizumab, Atezolizumab and Recombinant Human Hyaluronidase, Biospecimen Collection, Computed Tomography, Patient Observation
Biological · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
120
States / cities
Beverly Hills, California • Los Angeles, California • Tarzana, California + 100 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 31, 2026, 10:29 PM EDT
Completed Phase 1 Interventional

Safety Study of a Genetically Modified Adenovirus in Ovarian Cancer Patients

NCT00562003
View directory record Official record
Conditions
Ovarian Cancer, Primary Peritoneal Cancer
Interventions
Tenckhoff Catheter placement, Ad5-delta24RGD
Procedure · Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 26, 2011 · Synced Oct 31, 2026, 10:29 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

NCT04034927
View directory record Official record
Conditions
Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma, Malignant Ovarian Endometrioid Tumor, Ovarian High Grade Serous Adenocarcinoma, Platinum-Sensitive Fallopian Tube Carcinoma, Platinum-Sensitive Ovarian Carcinoma, Platinum-Sensitive Primary Peritoneal Carcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian Serous Adenocarcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Tremelimumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
20
States / cities
Orange, California • Aurora, Colorado • Hartford, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 31, 2026, 10:29 PM EDT
Terminated Early Phase 1 Interventional

11C Topotecan PET Imaging

NCT00253461
View directory record Official record
Conditions
Lung Cancer, Metastatic Cancer, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
computed tomography, positron emission tomography, 11C topotecan, fludeoxyglucose F 18
Procedure · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 20, 2012 · Synced Oct 31, 2026, 10:29 PM EDT
Completed Phase 1 Interventional

Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies

NCT01243359
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage I Renal Cell Cancer, Stage II Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
sunitinib malate, bevacizumab, pharmacological study, laboratory biomarker analysis, fluorine F 18 fluorothymidine, positron emission tomography, computed tomography
Drug · Biological · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
2
States / cities
Baltimore, Maryland • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 2, 2014 · Synced Oct 31, 2026, 10:29 PM EDT